08/20/2024
Hogan Lovells advises Merck as it enters into definitive agreement to acquire CN201, an autoimmune treatment drug
Merck plans to evaluate CN201 as a treatment for B-cell malignancies as well as investigate its potential to provide a novel, scalable option for the treatment of autoimmune diseases.